We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

103 hedge funds and large institutions have $147M invested in Xeris Biopharma Holdings in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

909% more call options, than puts

Call options by funds: $2.49M | Put options by funds: $247K

110% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 10

82% more capital invested

Capital invested by funds: $80.4M → $147M (+$66.1M)

12% more funds holding

Funds holding: 92 → 103 (+11)

4.7% more ownership

Funds ownership: 36.03% → 40.73% (+4.7%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 28

Holders
103
Holders Change
+11
Holders Change %
+11.96%
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
21
Increased
28
Reduced
28
Closed
10
Calls
$2.49M
Puts
$247K
Net Calls
+$2.25M
Net Calls Change
+$1.65M

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$10.1M
2
SCM
Soleus Capital Management
Connecticut
+$5.23M
3
Millennium Management
Millennium Management
New York
+$4.61M
4
BlackRock
BlackRock
New York
+$2.35M
5
EI
EAM Investors
California
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$7.99M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.18M
3
CC
Caxton Corporation
New Jersey
-$1.01M
4
GCP
GSA Capital Partners
United Kingdom
-$720K
5
RCMNY
Rubric Capital Management (New York)
New York
-$695K
Name Holding Trade Value Shares
Change 		Change in
Stake
SWA
101
SOA Wealth Advisors
New York
$309 – – –
Zurich Cantonal Bank
102
Zurich Cantonal Bank
Switzerland
$31 – – –
RCMNY
103
Rubric Capital Management (New York)
New York
– -$695K -426,267 Closed
XT
104
XTX Topco
Cayman Islands
– -$380K -233,385 Closed
YCM
105
Yakira Capital Management
Connecticut
– -$147K -90,076 Closed
MIM
106
MetLife Investment Management
New Jersey
– -$116K -71,237 Closed
SG Americas Securities
107
SG Americas Securities
New York
– -$67K -40,947 Closed
KCPG
108
Kavar Capital Partners Group
Kansas
– -$27.7K -17,000 Closed
GIA
109
Gladstone Institutional Advisory
Florida
– -$17.1K -10,500 Closed
MLICM
110
Metropolitan Life Insurance Company (MetLife)
New York
– -$11.9K -7,329 Closed
TFGT
111
TS Financial Group (TSFG)
Illinois
– -$9K -5,488 Closed
TWA
112
TCI Wealth Advisors
Arizona
– -$326 -200 Closed
FGAM
113
Financial Gravity Asset Management
Texas
– +$8 +3 New
1 2 3 4
5

XERS Hedge Fund Activity: Q2 2023 in Review

103 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2023, worth a combined $147M — up 82% from $80.4M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new XERS positions and 10 closed out — a net gain of 11 holders — while 28 added to existing stakes and 28 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $10.1M. The largest seller was Stonepine Capital Management, cutting an estimated $7.99M.

  • 103 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2023, up from 92 in Q1 2023.
  • Funds reported $147M of Xeris Biopharma Holdings stock for Q2 2023, up 82% quarter-over-quarter.
  • 21 funds opened new Xeris Biopharma Holdings positions in Q2 2023 and 10 closed out, a net change of +11 holders.
  • The largest Xeris Biopharma Holdings buyer in Q2 2023 was MPM BioImpact, an estimated $10.1M added.
  • The largest Xeris Biopharma Holdings seller in Q2 2023 was Stonepine Capital Management, an estimated $7.99M sold.

Based on aggregated 13F filings for Q2 2023.